
La informació completa de cada convocatòria la trobareu fent clic en el codi respectiu. Si teniu problemes d'accés amb l'enllaç, podeu tallar i apegar l'adreça completa al vostre navegador.

Els terminis de presentació de propostes finalitzen en els dies esmentats a les 17 hores (hora local de Brussel·les)

**PROGRAMA ESPECÍFIC DE COOPERACIÓ**

**Tema: Salut**

Tres convocatòries:

- FP7-HEALTH-2010-single-stage

**Pressupost indicatiu:** 333.500.000 euros

**Final del termini:** 19 de novembre de 2009

**Temes convocats:**

1. **BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH.**
   1.1. High-throughput research. 1.1-1: Harmonisation of phenotyping and biosampling for human large-scale research biobanks. 2010.1.1-3: High-throughput analysis of posttranslational modifications of proteins. 1.2. Detection, diagnosis and monitoring. 1.2-2: Stratification approaches and methodologies to select from a wide range of biomarkers relevant candidates for clinical validation. 1.2-3: Harmonization, validation and standardisation in genetic testing. 1.2-4: Early events in acute hepatitis C virus (HCV) infection with the aim to identify new biomarkers. 1.4. Innovative therapeutic approaches and interventions. 1.4-1: Translational research on cell-based immunotherapy. 2. TRANSLATING RESEARCH FOR HUMAN HEALTH. 2.1. Large-scale data gathering and systems biology. 2.1.1. Large-Scale Data Gathering 2.1.1-1: Large-scale efforts in mouse functional genomics to determine the functions of genes and their involvement in disease. 2.1.1-2: Coordination action(s) on standards in large scale data gathering. 2.1.2. Systems Biology 2.1.2-3: Developing new and improving existing mathematical algorithms for systems biology. 2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING. 2.2.2. Human development and ageing 2.2.2-5: Frailty and its implications in modern society. 2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH. 2.3.2. HIV/AIDS, malaria and tuberculosis 2.3.2-1: Target characterisation and hit-to-lead progression in tuberculosis (TB) drug development. 2.3.2-2: Lead optimisation and late preclinical development in tuberculosis (TB) drugs. 2.3.2-3. European network of cohort studies on HIV/AIDS. 2.3.3. Potentially new and re-emerging epidemics 2.3.3-1: Biology and control of vectorborne infections in Europe. 2.3.3-2: Drug lead discovery against RNA viruses. 2.3.3-3: Integrated disease-specific research on West Nile Virus infections, Chikungunya and/or Crimean Congo Haemorrhagic Fever. 2.3.4 Neglected infectious diseases 2.3.4-1: Vaccines for childhood bacterial diarrhoeal diseases. 2.3.4-2: Comprehensive control of Neglected Infectious Diseases. 2.3.4-3: Next generation of researchers for Neglected Infectious Diseases. 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES 2.4.1. Cancer 2.4.1-2: Structuring translational cancer research between cancer research centres in Europe. 2.4.1-3: Structuring clinical research in paediatric and adolescent oncology in Europe. 2.4.2. Cardiovascular diseases 2.4.2-1: Reducing in-stent thrombosis. 2.4.2-2: New approaches to reduce ischemic damage
to the heart. 2.4.2-3: Identifying new therapeutic targets in atrial fibrillation. 2.4.2-4: Diastolic heart failure. 2.4.4: Rare diseases. 2.4.4-1: Clinical development of substances with a clear potential as orphan drugs. 2.4.5: Other chronic diseases 2.4.5-1: Investigation of the mechanisms of initiation of allergic response, genetic predisposition, biomarkers and identification of targets for therapy. 2.4.5-2: Infection and dysbiosis as the triggers of the development of inflammatory processes in allergies and autoimmune diseases.

OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS 3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS 3.2-1: Financing systems' effect on quality of healthcare. 3.2-2: Risk adjustment algorithms for better health insurance coverage. 3.4. INTERNATIONAL PUBLIC HEALTH & HEALTH SYSTEMS. 3.4-5: Assessment of migrants' health, disease patterns and impact on health systems 3.4-6: Impact and cost-effectiveness of existing major health programmes.

OTHER ACTIONS ACROSS THE THEME 4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME. 4.1-1: Promoting participation of high-technology research-intensive SMEs, operating in the health sector. 4.2. RESPONDING TO EU POLICY NEEDS. 4.2-1: Off-patent medicines for children. 4.2-2: International paediatric initiative. 4.2-3: Adverse drug reaction research. 4.2-4: International pluripotent stem cell registry. 4.2-5: Methodology to evaluate and monitor health policy implementation and performance of EU funded interventions in developing countries. 4.2-6: Impact of EU legislation on health research. 4.2-7: International forum for European life sciences funders and performers. 4.2-8: Coordination action in support of the implementation by participating States of a Joint Programming Initiative for combating neurodegenerative diseases, in particular Alzheimer's disease.

Esquemes de finançament: diferents segons el tema, consultar el text complet de la convocatòria.

FP7-HEALTH-2010-two-stage
Pressupost indicatiu: 205.000.000 euros
Final del termini: 29 d'octubre de 2009 (primera fase)
Temes convocats: 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH. 1.2. Detection, diagnosis and monitoring. 1.2-1: Tools for the identification and the detection of biomarkers in clinical samples and patients. 2. TRANSLATING RESEARCH FOR HUMAN HEALTH. 2.1. Large-scale date gathering and systems biology. 2.1.2: Tackling Human Diseases through Systems Biology Approaches. 2.1.2-1: Establishing the foundations to enable systems biology of complex biological processes relevant to human health. 2.2. Research on the brain and related diseases, human development and ageing. 2.2.2-1: Role of early-life developmental processes in longevity determination. 2.2.2-2: Homeostasis in human development and its effects on lifespan. 2.2.2-3: Integrative systems biology and comparative genomics for studying human ageing. 2.2.2-4: Markers of cellular senescence for human ageing. 2.4. Translational research in other major diseases. 2.4.1-5: Structuring clinical research on rare cancers in adults. 2.4.1-6: Translational research on cancers with poor prognosis. 2.4.1-7: Predicting long-term side effects to cancer therapy. 2.4.1-8: Predicting individual response and resistance to cancer therapy. 2.4.1-9: Optimising the delivery of (chemo)radiotherapy and/or surgery to cancer patients. 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS. 3.1. Translating the results of clinical research outcome into clinical practice Including better use of medicines, and appropriate use of behavioural and Organisational interventions and new health therapies and technologies. 3.1-1: Better understanding of dissemination and implementation strategies.

Esquemes de finançament: diferents segons el tema, consultar el text complet de la convocatòria.

FP7-HEALTH-2010-Alternative-Testing
Pressupost indicatiu: 25.000.000 euros
Final del termini: 3 de febrer de 2010
Temes convocats: 4. OTHER ACTIONS ACROSS THE HEALTH THEME. 4.2. RESPONDING TO EU POLICY NEEDS 4.2c Alternative Testing. 4.2.9 Towards the replacement of repeated dose systemic toxicity testing in human safety assessment. 4.2.9.1 Optimisation of current methodologies and development of novel methods to achieve functional differentiation of
human-based target cells in vitro. 4.2.9.2 Exploitation of organ-simulating cellular devices as alternatives for long-term toxicity testing.

Esquemes de finançament: diferents segons el tema, consultar el text complet de la convocatòria.

CONVOCATÒRIES CONJUNTES

FP7-AFRICA-2010 (Salut. Medi ambient. Aliments, agricultura i pesca, i biotecnologia.)

Pressupost indicatiu: 63.000.000 euros (per al tema Salut, 39.000.000 euros)
Final del termini: 14 de gener de 2010
Temes convocats: ACTIVITY 1.2 TRANSLATING RESEARCH FOR HUMAN HEALTH. 2.3.2-4: Controlling malaria by hitting the vector: New or improved – Vector Control Tools. 2.4.1-4: Infectious agents and cancer in Africa ACTIVITY 1.3 INTERNATIONAL PUBLIC HEALTH AND HEALTH SYSTEMS. 3.4-1: Develop and assess key interventions and policies to address the human resource crisis in the health sector. 3.4-2: Feasibility and community effectiveness of innovative intervention packages for maternal and new-born health in Africa. 3.4-3: Building sustainable capacity for research for health in Africa. 3.4-4: Assessment of migrants' health, disease patterns and impact on health systems.

Esquemes de finançament: diferents segons el tema, consultar el text complet de la convocatòria.

FP7-INFLUENZA-2010 (Salut. Aliments, agricultura i pesca, i biotecnologia.)

Pressupost indicatiu: 18.000.000 euros (per al tema Salut, 12.000.000 euros)
Final del termini: 29 d'octubre de 2009
Temes convocats: ACTIVITY 2.3.3: POTENTIALLY NEW AND REEMERGING EPIDEMICS. 2.3.3-4: Novel therapeutics against influenza.

Esquemes de finançament: projectes col·laboratius de petita o mitjana escala.

Més informació: Ángeles Sanchis, ext. 51276.

Oficina de Projectes Europeus de Recerca
Universitat de València
Campus de Blasco Ibáñez
Av. Menéndez y Pelayo, 3-5, planta primera
46010 València
Tel. 96-3983621
http://www.uv.es/operuv
operuv@uv.es

Aquest missatge ha estat distribuït a la llista EUROSALUT. Per a subscriure's-hi, envieu un missatge a l'adreça listserv@listserv.uv.es amb el següent text: subscribe EUROSALUT Nom Cognoms. Per a cancel·lar la subscripció, envieu un missatge a l'adreça listserv@listserv.uv.es amb el text: signoff EUROSALUT.